2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Dickran G. Kazandjian, MD, professor of medicine, Myeloma Program, Sylvester Comprehensive Cancer Center, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.
Retreatment with BCMA-targeted therapies is a reasonable therapeutic strategy for patients with multiple myeloma and is being adopted in clinical practice, says Kazandjian. Utilizing different modalities of BCMA-directed therapies may offer patients valuable treatment options, Kazandjian says.
However, evaluating BCMA-directed therapy retreatment has been challenging in the setting of clinical trials because many studies exclude relevant patients, says Kazandjian. For example, a study evaluating a BCMA-directed antibody-drug conjugate may exclude patients who received prior BCMA-directed CAR T-cell therapy, Kazandjian explains.
If initial efficacy and safety signals emerge suggesting retreatment is feasible, clinical trial inclusion criteria may become less conservative, Kazandjian says. A similar clinical scenario was observed with the CD38-targeted monoclonal antibodies daratumumab (Darzalex) and isatuximab-irfc (Sarclisa), concludes Kazandjian.
Related Content: